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JAAD ONLINE: NOTES & COMMENTS
Tapinarof-associated folliculitis is
generally mild, self-limiting, and
rarely interferes with therapy
To the Editor: We thank Konstantinou et al1 for their
interest in our article on the mechanism of action of
tapinarof. We appreciate the opportunity to clarify
and share information on folliculitis observed in
tapinarof clinical trials, as this is completely different
from dioxin-induced chloracne or hidradenitis
suppurativa.
Konstantinou et al1 draw associations between
tapinarof and dioxin-like compounds based on their
aryl hydrocarbon receptor (AhR)-binding activity.
However, since AhR is a ligand-dependent
transcription factor, any downstream effects are
highly dependent on the molecule to which it binds.
Therefore, the mechanisms underlying the efficacy
and safety of tapinarof in psoriasis are distinct from
dioxins and other AhR-binding ligands.
Tapinarof is a naturally identified topical
therapeutic AhR modulating agent, thus different
from pathologic AhR modulating agents, such as the
manmade toxin, dioxin. Tapinarof and dioxins bind
at distinctly different sites on the AhR complex,
modulate different genes and pathways, and cause
vastly different downstream effects.2,3 Moreover,
tapinarof has limited systemic exposure as
demonstrated by maximal use pharmacokinetic
studies.4
Information on folliculitis has been obtained from
more than 2200 patients in 18 tapinarof clinical trials.
Across all trials, the incidence, morphology, and
severity of folliculitis have remained consistent. In
the most recent, pivotal, phase 3 psoriasis trials in
1025 patients,3 the adverse event associated with
tapinarof was folliculitis, which was mostly mild,
resulted in a low incidence of study discontinuation
(\1.8%), was localized to the hair follicle, and was
not associated with a higher frequency in areas
prone to acne. Therefore, localized folliculitis in
these studies was not analogous to hidradenitis
suppurativa5 or the lesions seen in chloracne, which
involve the sebaceous glands. Sebaceous gland
atrophy has never been observed with tapinarof in
any preclinical in vivo studies, regardless of the route
of delivery, including chronic exposure.
In summary, evidence with tapinarof is not
supportive of the associations proposed by
Konstantinou et al,1 and the clinical data demon-
strates that tapinarof-associated folliculitis is generally
mild, self-limiting, and rarely interferes with therapy.
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